Eli Lilly: Buying Opportunity Knocking On The Front Door Again (Rating Upgrade)
Eli Lilly (LLY) reported strong first-quarter results with 56% revenue growth and earnings per share of $8.55, driven by robust demand for its diabetes and obesity drugs. The company's promising pipeline and commercial momentum have led to a rating upgrade, highlighting improved investor sentiment. Despite valuation concerns, analysts view the current market pullback as a potential buying opportunity.
- ▪Eli Lilly reported 56% year-over-year revenue growth in Q1.
- ▪The company achieved earnings per share of $8.55 in the first quarter.
- ▪Strong sales of diabetes and obesity drugs like Mounjaro and Zepbound fueled the performance.
- ▪Analysts have upgraded Eli Lilly's stock rating due to its growth trajectory and pipeline potential.
- ▪The stock faces valuation concerns but is seen as a long-term growth play.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4897349-eli-lilly-buying-opportunity-knocking-on-the-front-door-again-upgrade"},"author":{"@type":"Person","name":"JR…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
